We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antioxidant Reduces Brain Damage from Stroke

By HospiMedica staff writers
Posted on 17 Oct 2002
A synthetic antioxidant has been shown to reduce brain damage by more than 40% in an animal model of stroke when given seven and a half hours after the stroke begins. More...
The research was reported in the October 2002 issue of Free Radical Biology and Medicine.

Following a stroke, many of the cells that are injured but not killed by oxygen deprivation die in the hours following the stroke. Free radicals kill many of those cells. The researchers used a synthetic antioxidant, called AEOL 10150, to neutralize the damaging free radicals and reduce cell death in a mouse model of stroke. This antioxidant mimics the naturally occurring antioxidant superoxide dismutase but is effective against a wider range of oxygen radicals and lasts longer in the body.

The researchers blocked the middle cerebral artery of rats for 90 minutes, then injected AEOL 10150 or a placebo into their brains six hours after the artery had been reopened. When evaluated a week later, the animals who received the placebo had an average of 160 cubic mm of brain tissue destroyed by the stroke, while those who received the antioxidant has an average of only 92 cubic mm of brain tissue destroyed, or 43% less.

"Our findings suggest that the antioxidant is a promising candidate for stroke therapy because it can prevent damage so many hours after the stroke begins,” said James Crapo, M.D., coauthor of the study and chairman of the department of medicine at National Jewish Medical (Denver, CO, USA). The new antioxidant was created by Dr. Crapo and colleagues at Duke University (Durham, NC, USA).




Related Links:
National Jewish Medical
Duke University Med Ctr.

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.